Brigatinib

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 520 publications

Quantitative imaging of schwannoma captures heterogeneity and accelerates preclinical testing, revealing distinct impacts of targeted therapies.

Quantitative imaging of schwannoma captures heterogeneity and accelerates preclinical testing, revealing distinct impacts of targeted therapies.

Journal: bioRxiv : the preprint server for biology

Published: April 03, 2026

Inhibition of Four Anaplastic Lymphoma Kinase Inhibitors on the Activity of Human UDP-Glucuronosyltransferases and Prediction of Drug-Drug Interactions.

Inhibition of Four Anaplastic Lymphoma Kinase Inhibitors on the Activity of Human UDP-Glucuronosyltransferases and Prediction of Drug-Drug Interactions.

Journal: Chemical research in toxicology

Published: February 27, 2026

N-Cadherin Dynamically Regulates Schwannoma Migration and Represents a Novel Therapeutic Target in NF2-Related Schwannomatosis.

N-Cadherin Dynamically Regulates Schwannoma Migration and Represents a Novel Therapeutic Target in NF2-Related Schwannomatosis.

Journal: Research square

Published: February 27, 2026

GARD: Genomic Data based Drug Repurposing in Head and Neck Cancer with Large Language Model Validation.

GARD: Genomic Data based Drug Repurposing in Head and Neck Cancer with Large Language Model Validation.

Journal: bioRxiv : the preprint server for biology

Published: February 06, 2026

Cost of managing brain metastases in ALK-positive advanced NSCLC patients receiving first-line ALK TKIs in China.

Cost of managing brain metastases in ALK-positive advanced NSCLC patients receiving first-line ALK TKIs in China.

Journal: Lung cancer management

Published: February 03, 2026

GARD: Genomic Data-Based Drug Repurposing in Head and Neck Cancer with Large Language Model Validation.

GARD: Genomic Data-Based Drug Repurposing in Head and Neck Cancer with Large Language Model Validation.

Journal: Cancers

Published: January 16, 2026

A New Class of Multitargeting PtIV Anticancer Agents: Prodrugs That Release PtII Drugs and Bioactive Moieties Tethered to PtIV via a Tertiary Amine.

A New Class of Multitargeting PtIV Anticancer Agents: Prodrugs That Release PtII Drugs and Bioactive Moieties Tethered to PtIV via a Tertiary Amine.

Journal: Journal of medicinal chemistry

Published: January 15, 2026

Polyhedral alkanes as hydrophobic tags for dual-functional ALK inhibitor-degrader.

Polyhedral alkanes as hydrophobic tags for dual-functional ALK inhibitor-degrader.

Journal: Bioorganic chemistry

Published: January 15, 2026

Dual FAK and EPHA2 targeting by brigatinib tackles PARP inhibitor adaptive survival response in high-grade serous ovarian cancer.

Dual FAK and EPHA2 targeting by brigatinib tackles PARP inhibitor adaptive survival response in high-grade serous ovarian cancer.

Journal: Science translational medicine

Published: January 14, 2026

Emerging Molecular Insights and Therapeutic Directions in Neurofibromatosis Type 1 and NF2-Related Schwannomatosis.

Emerging Molecular Insights and Therapeutic Directions in Neurofibromatosis Type 1 and NF2-Related Schwannomatosis.

Journal: International journal of molecular sciences

Published: January 09, 2026

A novel pan class-I glucose transporter inhibitor DRB18 exhibits synergistic effects with paclitaxel in vitro and in vivo against human non-small cell lung cancer.

A novel pan class-I glucose transporter inhibitor DRB18 exhibits synergistic effects with paclitaxel in vitro and in vivo against human non-small cell lung cancer.

Journal: bioRxiv : the preprint server for biology

Published: January 08, 2026

Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial.

Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial.

Journal: Future oncology (London, England)

Published: December 18, 2025

Showing 1-12 of 520

Last Updated: 04/28/2026